Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: OTC US
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Neurologix Inc

+ Add to Watchlist

NRGXQ:US

0.0010 USD 0.0030 75.00%

As of 20:10:00 ET on 03/18/2015.

Company Profile for Neurologix Inc (NRGXQ)

Neurologix, Inc. is developing treatments for disorders of the brain and central nervous system using gene therapy and other alternative therapies. The Company's initial development efforts are focused on gene therapy for treating Parkinson's disease and epilepsy. Neurologix's core technology, NLX, is currently being tested in a human clinical trial to treat Parkinson's disease.

Contact Information

Neurologix Inc

One Bridge Plaza
Suite 605
Fort Lee, NJ 07024
United States
Phone: 1-201-592-6451
Fax: 1-201-592-0366

Key Executives for Neurologix Inc (NRGXQ)

Clark A JohnsonChairman/CEOChristine V SapanExec VP/Chief Development Ofcr

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Advertisements
Advertisement
sec ||= nil